Tobi is a medicine prescribed to treat a bacterial infection caused by Pseudomonas aeruginosa in those who have cystic fibrosis. This prescription medicine comes as a liquid that is inhaled twice daily using a nebulizer and an air compressor. Side effects include a sore throat, increased coughing, and a stuffy or runny nose.
Tobi® (tobramycin inhalation solution) is a prescription medication approved to treat people with cystic fibrosis who have a type of bacteria in their lungs called Pseudomonas aeruginosa. Tobi is an inhaled aminoglycoside antibiotic.
Tobi also comes as a dry powder capsule that is inhaled using a special device (please see Tobi Podhaler for more information about that product).
Tobi is made by Novartis Pharmaceuticals Corporation.
Tobi works by killing bacteria. It does this by interfering with the ability of the bacteria to make proteins, which are necessary for the bacteria to grow and multiply.
Tobi has been studied in clinical trials that included people with cystic fibrosis who had the bacteria P. aeruginosa in their lungs. People in the studies were randomly assigned to receive either Tobi or a placebo (an inhaled "medicine" with no active ingredients) for three cycles. Each cycle consisted of 28 days using the drug, followed by 28 days when no drug was given.
In these clinical studies, Tobi improved lung function more so than the placebo. In addition, people given Tobi were hospitalized for 5.1 days, on average, compared with 8.1 days for those given the placebo. Over the six months of treatment, 40 percent of those treated with Tobi needed to also be treated with intravenous antibiotics for their infection, compared with 53 percent of those using the placebo.